ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2022 American Transplant Congress
    • 2021 American Transplant Congress
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2021 Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Search

Effectiveness and Tolerability of Cidofovir for the Management of BK Viremia in Kidney Transplant Recipients

M. Thornberg1, J. Hedvat1, N. Lange1, C. Brennan2, D. Salerno1, D. Tsapepas2

1NewYork-Presbyterian Hospital, Department of Pharmacy, New York, NY, 2Columbia Irving University Medical Center, Department of Transplant Surgery, New York, NY

Meeting: 2020 American Transplant Congress

Abstract number: C-207

Keywords: Graft failure, Infection, Kidney transplantation, Polyma virus

Session Information

Session Name: Poster Session C: Kidney: Polyoma

Session Type: Poster Session

Date: Saturday, May 30, 2020

Session Time: 3:15pm-4:00pm

 Presentation Time: 3:30pm-4:00pm

Location: Virtual

*Purpose: BK viremia (BKV) is a common complication after kidney transplantation (KT) that often leads to graft dysfunction and loss. Without consensus management guidelines and large randomized trials to assess BKV management, the efficacy of various strategies remain unclear. Our study aims to evaluate effectiveness and tolerability associated with the use of cidofovir for BKV treatment in a large cohort of KT recipients.

*Methods: This single-center retrospective cohort study of all KT recipients who received cidofovir for BKV between Jan 2015 and July 2019 was approved by the IRB. The primary outcome was incidence of BKV clearance within 3 months of cidofovir initiation. Descriptive statistics were performed to assess characteristics of the cohort.

*Results: During the period of study, 27 KT recipients with BKV received cidofovir. Patient demographics and BKV characteristics are summarized in Table 1. Changes in immunosuppression before and after BKV diagnosis are shown in Table 2. The median peak BK viral load prior to cidofovir administration was 77,580 copies/mL (IQR 28,358-322,318). Median time to cidofovir initiation after BKV diagnosis was 83 days (IQR 54-114), and treatment duration was 157 days (IQR 82-365). 17 patients (63%) received concomitant IVIG and median time to initiation was 2 months (IQR 1-3). Fluoroquinolones were used in 11 patients (41%) and initiated 4 months (IQR 2-6) after BKV diagnosis. Median time to clearance after BKV diagnosis was 19 months (IQR 12-25). Incidence of BKV clearance 3 months after cidofovir initiation occurred in 1 of 23 patients (4%) with available data. 5 of 13 patients (38%) cleared BKV at 12 months after cidofovir initiation. 6 patients (22%) experienced graft failure, of which 4 cases were due to BKV nephropathy. The median time to graft failure was 1030 days (IQR 625-1388). 96% of patients were alive at time of last follow-up. Median time to last follow-up was 1075 days (IQR 767-1530).

*Conclusions: Initiation of cidofovir did not appear to impact rate of BKV clearance by 3 months in our cohort. Further assessments will be completed to identify factors associated with BKV clearance in KT recipients.

 border=

  • Tweet
  • Email
  • Print

To cite this abstract in AMA style:

Thornberg M, Hedvat J, Lange N, Brennan C, Salerno D, Tsapepas D. Effectiveness and Tolerability of Cidofovir for the Management of BK Viremia in Kidney Transplant Recipients [abstract]. Am J Transplant. 2020; 20 (suppl 3). https://atcmeetingabstracts.com/abstract/effectiveness-and-tolerability-of-cidofovir-for-the-management-of-bk-viremia-in-kidney-transplant-recipients/. Accessed May 11, 2025.

« Back to 2020 American Transplant Congress

Visit Our Partner Sites

American Transplant Congress (ATC)

Visit the official site for the American Transplant Congress »

American Journal of Transplantation

The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

American Society of Transplantation (AST)

An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

American Society of Transplant Surgeons (ASTS)

The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

Copyright © 2013-2025 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

Privacy Policy | Terms of Use | Cookie Preferences